Pharmerica (PMC) Tops Q1 EPS by 2c; Reaffirms

Pharmerica (NYSE: PMC) reported Q1 EPS of $0.42, $0.02 better than the analyst estimate of $0.40. Revenue for the quarter came in at $566.8 million versus the consensus estimate of $536.89 million.

PharMerica reaffirms its full year 2017 guidance metrics:

• Revenue in the range of $2.3 billion to $2.4 billion;
• Adjusted EBITDA in the range of $132.0 million to $142.0 million; and
• Adjusted diluted earnings per share in the range of $1.75 to $1.95.

For earnings history and earnings-related data on Pharmerica (PMC) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SanDisk upgraded at JPMorgan after investor day; shares climb
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15